Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2022;46(1):108-118 - PMID: 36266539 - PMCID: PMC9747611 - DOI: 10.1038/s41440-022-01070-4

Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ, BrigHTN Investigators Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2022;388(5):395-405 - PMID: 36342143 - DOI: 10.1056/NEJMoa2213169

Halvorsen YD, Lock JP, Frias JP, Tinahones FJ, Dahl D, Conery AL, Freeman MW A 96-Week, Double-Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults. Diabetes Obes Metab. 2022;25(1):293-301 - PMID: 36178197 - DOI: 10.1111/dom.14875